Stemtech Valuation
| STEK Stock | USD 0.05 0 5.66% |
Stemtech seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Stemtech from inspecting the company fundamentals such as Return On Asset of -0.75, current valuation of 8.79 M, and Revenue of 4.32 M as well as reviewing its technical indicators and probability of bankruptcy. . In general, most investors recommend picking up undervalued stocks and discarding overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Overvalued
Today
Please note that Stemtech's price fluctuation is out of control at this time. Calculation of the real value of Stemtech is based on 3 months time horizon. Increasing Stemtech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Stemtech otc stock is determined by what a typical buyer is willing to pay for full or partial control of Stemtech. Since Stemtech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Stemtech OTC Stock. However, Stemtech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.05 | Real 0.038 | Hype 0.05 | Naive 0.0416 |
The intrinsic value of Stemtech's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Stemtech's stock price.
Estimating the potential upside or downside of Stemtech helps investors to forecast how Stemtech otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Stemtech more accurately as focusing exclusively on Stemtech's fundamentals will not take into account other important factors: Stemtech Total Value Analysis
Stemtech is at this time forecasted to have valuation of 8.79 M with market capitalization of 6.52 M, debt of 219.47 K, and cash on hands of 399.73 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Stemtech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.79 M | 6.52 M | 219.47 K | 399.73 K |
Stemtech Investor Information
About 64.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Stemtech is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Stemtech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Stemtech has an asset utilization ratio of 75.54 percent. This suggests that the OTC Stock is making $0.76 for each dollar of assets. An increasing asset utilization means that Stemtech is more efficient with each dollar of assets it utilizes for everyday operations.Stemtech Ownership Allocation
Stemtech shows a total of 48.63 Million outstanding shares. Stemtech has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 63.6 % of Stemtech outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Stemtech Profitability Analysis
The company reported the previous year's revenue of 4.32 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 3.3 M.About Stemtech Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Stemtech. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of Stemtech based exclusively on its fundamental and basic technical indicators. By analyzing Stemtech's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Stemtech's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Stemtech. We calculate exposure to Stemtech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Stemtech's related companies.Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Stemtech's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Stemtech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Stemtech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Stemtech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Stemtech's revenue streams: Identify Stemtech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Stemtech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Stemtech's growth potential: Evaluate Stemtech's management, business model, and growth potential.
- Determine Stemtech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Stemtech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Stemtech Growth Indicators
Investing in growth stocks can be very risky. If the company such as Stemtech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 37.6 M | |
| Retained Earnings | -13.1 M |
Other Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.